Logo image of TYRA

TYRA BIOSCIENCES INC (TYRA) Stock Fundamental Analysis

NASDAQ:TYRA - Nasdaq - US90240B1061 - Common Stock - Currency: USD

10.78  -0.03 (-0.28%)

After market: 10.45 -0.33 (-3.06%)

Fundamental Rating

3

Taking everything into account, TYRA scores 3 out of 10 in our fundamental rating. TYRA was compared to 556 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TYRA as it has an excellent financial health rating, but there are worries on the profitability. TYRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TYRA had negative earnings in the past year.
TYRA had a negative operating cash flow in the past year.
TYRA had negative earnings in each of the past 5 years.
TYRA had a negative operating cash flow in each of the past 5 years.
TYRA Yearly Net Income VS EBIT VS OCF VS FCFTYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of TYRA (-28.08%) is better than 69.06% of its industry peers.
The Return On Equity of TYRA (-29.81%) is better than 78.24% of its industry peers.
Industry RankSector Rank
ROA -28.08%
ROE -29.81%
ROIC N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
TYRA Yearly ROA, ROE, ROICTYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TYRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TYRA Yearly Profit, Operating, Gross MarginsTYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for TYRA has been increased compared to 1 year ago.
Compared to 5 years ago, TYRA has more shares outstanding
There is no outstanding debt for TYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TYRA Yearly Shares OutstandingTYRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TYRA Yearly Total Debt VS Total AssetsTYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

TYRA has an Altman-Z score of 16.15. This indicates that TYRA is financially healthy and has little risk of bankruptcy at the moment.
TYRA's Altman-Z score of 16.15 is amongst the best of the industry. TYRA outperforms 91.37% of its industry peers.
TYRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.15
ROIC/WACCN/A
WACCN/A
TYRA Yearly LT Debt VS Equity VS FCFTYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

TYRA has a Current Ratio of 22.78. This indicates that TYRA is financially healthy and has no problem in meeting its short term obligations.
TYRA has a Current ratio of 22.78. This is amongst the best in the industry. TYRA outperforms 95.50% of its industry peers.
A Quick Ratio of 22.78 indicates that TYRA has no problem at all paying its short term obligations.
The Quick ratio of TYRA (22.78) is better than 95.50% of its industry peers.
Industry RankSector Rank
Current Ratio 22.78
Quick Ratio 22.78
TYRA Yearly Current Assets VS Current LiabilitesTYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

TYRA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.98%.
EPS 1Y (TTM)2.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TYRA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.97% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-43.04%
EPS Next 2Y-26.73%
EPS Next 3Y-20.31%
EPS Next 5Y37.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TYRA Yearly Revenue VS EstimatesTYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B
TYRA Yearly EPS VS EstimatesTYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TYRA. In the last year negative earnings were reported.
Also next year TYRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TYRA Price Earnings VS Forward Price EarningsTYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TYRA Per share dataTYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as TYRA's earnings are expected to decrease with -20.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.73%
EPS Next 3Y-20.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TYRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TYRA BIOSCIENCES INC

NASDAQ:TYRA (7/24/2025, 8:08:43 PM)

After market: 10.45 -0.33 (-3.06%)

10.78

-0.03 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners81.15%
Inst Owner Change-0.82%
Ins Owners3.61%
Ins Owner Change-0.6%
Market Cap573.28M
Analysts87.14
Price Target30.75 (185.25%)
Short Float %11.23%
Short Ratio15.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.08%
Min EPS beat(2)5.89%
Max EPS beat(2)12.26%
EPS beat(4)3
Avg EPS beat(4)10.13%
Min EPS beat(4)-0.82%
Max EPS beat(4)23.17%
EPS beat(8)5
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)7.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.94%
EPS NQ rev (1m)-1.4%
EPS NQ rev (3m)-0.41%
EPS NY rev (1m)-1.04%
EPS NY rev (3m)2.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS6.08
TBVpS6.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.08%
ROE -29.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.06%
ROA(5y)-28.43%
ROE(3y)-26.84%
ROE(5y)-31.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.37%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.78
Quick Ratio 22.78
Altman-Z 16.15
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.58%
Cap/Depr(5y)324.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.29%
EPS Next Y-43.04%
EPS Next 2Y-26.73%
EPS Next 3Y-20.31%
EPS Next 5Y37.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.54%
EBIT Next 3Y-20.04%
EBIT Next 5YN/A
FCF growth 1Y-43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.95%
OCF growth 3YN/A
OCF growth 5YN/A